Pharmacists Fight Back in Medicare and Medicaid Act
Summary
HR6609 is an early-stage bill that would mandate rebate pass-throughs and ban patient steering by PBMs in Medicare and Medicaid. The bill has 36 cosponsors but remains in committee since December 2025 with no further action — legislative probability is low near-term. Despite real headwinds for CVS, CI, UNH, and ELV, the market has rallied these names 3-10% in the past week and 8-42% in 30 days on unrelated earnings and sector rotation, not this bill.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6609 targets PBM rebate retention and steering in Medicare/Medicaid — structurally bearish for $CVS, $CI, $UNH, but currently stalled in committee with zero progress in 5 months.
- 2.Market data shows 3-10% weekly and 8-42% monthly gains across affected tickers — the rally is driven by earnings and sector rotation, not legislative risk.
- 3.No near-term action expected. The bill requires passage through two House committees, full House, Senate, and signature — a low-probability path in the current Congress.
Market Implications
Current prices ($CVS $83.3, $CI $287.69, $UNH $367.09, $ELV $372.94) reflect no material discount for HR6609 risk. The market is correctly assessing this as a low-probability, early-stage bill with a distant effective date (2027). However, if the bill gains unexpected momentum (e.g., committee markup scheduled, new cosponsor wave, Senate companion introduced), expect immediate repricing of these tickers to the downside by 2-5%. For now, the broader tailwinds (earnings, sector rotation) dominate price action. Investors should monitor Committee on Energy and Commerce calendar for any hearing or markup announcement — that would be the first real signal of legislative movement.
Full Analysis
-
WHAT HAPPENED: On December 11, 2025, Rep. Auchincloss (D-MA) introduced HR6609, the 'Pharmacists Fight Back in Medicare and Medicaid Act'. The bill would amend the Social Security Act to require PDP sponsors and their PBMs in Medicare Part D and Medicaid to pass through 100% of manufacturer rebates to the plan at the point of sale, and prohibit steering patients to PBM-owned or affiliated pharmacies. It has 36 cosponsors (bipartisan) and was referred to the Energy & Commerce and Ways & Means Committees. There have been zero actions since referral — the bill is stalled in early-stage committee review.
-
THE MONEY TRAIL: This bill authorizes no direct government spending. It is a regulatory mandate — it imposes compliance requirements on private entities (PBMs and health plans). The financial impact is a transfer of value from PBM margins to plan sponsors, beneficiaries (lower cost-sharing), and independent pharmacies. For the affected PBMs, the revenue impact is the loss of rebate spreads (estimated 1-3% of drug spend) and steering-related pharmacy profits. No appropriation is involved.
-
STRUCTURAL WINNERS AND LOSERS: Losers are the vertically integrated PBMs: CVS (Caremark, $83.3), CI (Express Scripts, $287.69), and UNH (Optum Rx, $367.09) — these derive significant profit from rebate retention and steering. ELV ($372.94) is less exposed as it lacks a large captive PBM but still faces compliance costs. Winners would be independent pharmacies (not publicly traded in aggregate) and potentially retail pharmacy chains not affiliated with major PBMs (Rite Aid, if still public; Walgreens ($WBA)). The bill does not directly benefit drug manufacturers.
-
MARKET DATA REALITY: Despite this legislative overhang, all four tickers have rallied strongly over the past 30 days: CVS +15.98%, CI +7.85%, UNH +35.66%, ELV +27.39%. Over 7 days: CVS +6.88%, CI +4.37%, UNH +3.43%, ELV +8.17%. These moves coincide with broader healthcare sector rotation and earnings releases — the market is essentially ignoring this bill as legislative noise at this stage.
-
TIMELINE: The bill has been dormant for nearly five months. It needs committee markups in both Energy & Commerce and Ways & Means, House floor passage, Senate introduction/passage, and presidential signature. The effective date (2027) is still two years out. Near-term legislative probability is below 10%. This is a monitoring item, not a trading catalyst.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Mandates rebate pass-through to payers at the point of sale and bans patient steering by PBMs under Medicare and Medicaid contracts for plan years beginning on or after January 1, 2027.
Who must act
PDP sponsors and any PBM acting on their behalf (including affiliates) in Medicare Part D and Medicaid managed care plans.
What happens
Eliminates PBM ability to retain spread between manufacturer rebates and negotiated discounts, and prohibits steering patients to PBM-owned pharmacies, directly compressing PBM profit margins on government drug coverage.
Stock impact
CVS Caremark is one of the three largest PBMs and operates the Caremark pharmacy network and CVS retail pharmacies; the bill would strip rebate retention revenue and limit steering to its own pharmacies, hitting both PBM and retail margin streams. Current stock price $83.3, up 6.88% (7d) and 15.98% (30d) — market is pricing unrelated tailwinds, not this risk.
What the bill does
Same as above — mandates rebate pass-through and bans patient steering for Medicare and Medicaid.
Who must act
PDP sponsors and PBMs under Medicare Part D and Medicaid managed care contracts.
What happens
Cigna's PBM (Express Scripts) would lose rebate spread retention and the ability to steer patients to its own pharmacies under government programs.
Stock impact
Cigna's PBM segment (Evernorth/Express Scripts) is a major profit contributor; rebate retention and network steering are core PBM revenue mechanisms. Stock at $287.69, up 4.37% (7d) and 7.85% (30d) — rally is unrelated. Potential margin compression from this bill is real but distant.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Association Health Plans Act
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Living Donor Protection Act of 2025
Medicare Advantage Prompt Pay Act
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act of 2025
Consolidated Appropriations Act, 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.